The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers 

Accreditation types: 1.75 ABIM MOC, ABS MOC, CME

Expires: June 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Ramez N Eskander

Faculty

Ramez N Eskander

MD

UC San Diego Health, Rebecca and John Moores NCI-Designated Comprehensive Cancer Center, San Diego, California

Julie St John Endowed Chair in Gynecologic Oncology, Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Clinical Trials Office Medical Director, Fellowship Director – Gynecologic Oncology

Bradley J Monk

Faculty

Bradley J Monk

MD

Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

Medical Director, Late-Phase Research Program

University of Central Florida College of Medicine, Orlando, Florida

Professor

GOG Foundation, West Palm Beach, Florida

Vice President and Member, Board of Directors

GOG Partners, West Palm Beach, Florida

Co-Director

Kathleen N Moore

Moderator

Kathleen N Moore

MD, MS

Fred and Pamela Buffett Cancer Center at the University of Nebraska, Omaha, Nebraska

Deputy Director and Director, Phase 1 Clinical Trials

TARGET AUDIENCE
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

LEARNING OBJECTIVES

  • Understand the structural components and mechanisms of action of novel antibody-drug conjugates (ADCs) under investigation for gynecologic cancers.
  • Appreciate the incidence of CDH6 expression in gynecologic cancers, and consider available research findings with and the potential role of novel ADCs targeting this newly emerging biomarker.
  • Recognize the biological rationale for and available data with TROP2-directed ADCs for patients with gynecologic cancers, and consider the potential role of these agents in disease treatment.
  • Compare and contrast the toxicities associated with novel ADCs under development for patients with gynecologic cancers, and appreciate available supportive management strategies to minimize or ameliorate these side effects.
  • Understand the mechanisms of resistance to available and emerging ADCs, and evaluate the impact this information may have on optimal selection and sequencing of therapies.
  • Recall the design of ongoing clinical trials evaluating novel ADCs for gynecologic cancers, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation components and a post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation components and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ramez N Eskander, MD

Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Foundation Medicine, Gilead Sciences Inc, GSK, ImmunoGen Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MSD, Myriad Genetic Laboratories Inc, Natera Inc, Novocure Inc, Pfizer Inc, pharmaand GmbH, PMV Pharma, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Xencor.

Bradley J Monk, MD

Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR
Kathleen N Moore, MD, MS

Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS —Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Merck.

Release date: June 2026
Expiration date: June 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Moore

Albiges L et al. REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors. ASCO 2025;Abstract TPS3158.

Coleman RL et al. Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis. ASCO 2025;Abstract 5579.

Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract

Moore K et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract LBA04.

Moore KN et al. Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study. ESMO Gynaecological Cancers 2025;Abstract 77MO.

Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. ESMO 2023;Abstract 745MO.

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

 

Prof Eskander

Bignotti E et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol 2012;12:22. Abstract

Bujnak AC et al. Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics. Gynecol Oncol 2025;195:180-91. Abstract

Dum D et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors. ESMO 2022;Abstract 83P.

Fu Z et al. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct Target Ther 2022;7(1):93. Abstract

Halle MK et al. TROP-2, TF and NECTIN4 as targets for ADC treatment in cervical cancer. ESMO 2024;Abstract 24MO.

Ruan D-Y et al. Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer Commun (Lond) 2024;44(1):3-22. Abstract

Wang R et al. Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals. J Hematol Oncol 2025;18(1):51. Abstract

Wen Y et al. A literature review of the promising future of TROP2: A potential drug therapy target. Ann Transl Med 2022;10(24):1403. Abstract

Zhou Y et al. Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: Similarities and differences. Cancer Chemother Pharmacol 2025;95(1):106. Abstract

 

Dr Monk

Hamagawa K et al. Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): Opportunities for targeted treatment strategies. ESMO Gynaecological Cancers 2025;Abstract 71O.

Lee J-Y et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study. IGCS 2023;Abstract 1550.

Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Monk B et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study. SGO 2026;Abstract.

Nguyen TD et al. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel) 2023;15(3):713. Abstract

Oaknin A et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study. ESMO 2024;Abstract 714MO.

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract

Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4). Abstract

Rugo HS et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 2022;7(4). Abstract

Santin AD et al. Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): Analysis in patients with advanced endometrial cancer. J Clin Oncol 2024;42(29):3421-9. Abstract

Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106. Abstract

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

Tarantino P et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review. JAMA Oncol 2021;7(12):1873-81. Abstract

Wang K et al. Sacituzumab tirumotecan monotherapy in advanced/metastatic endometrial carcinoma: Results from a phase 1/2 study (2870-001/KL264-01). IGCS 2025;Abstract.

Wang K et al. Sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced/metastatic endometrial carcinoma (EC): Results from a phase I/II study (MK-2870-001/KL264-01). ESMO 2025;Abstract 1111P.

Zhou K et al. Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies. J Hematol Oncol 2025;18:96. Abstract

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Ovarian Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Bradley J Monk

Faculty

Bradley J Monk

MD

Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

Medical Director, Late-Phase Research Program

University of Central Florida College of Medicine

Professor

GOG Foundation, West Palm Beach, Florida

Vice President and Member, Board of Directors

GOG Partners, West Palm Beach, Florida

Co-Director

Faculty

Kathryn M Schlenker

MSN, WHNP-BC, AGNP-C

The University of Alabama at Birmingham, Birmingham, Alabama

Nurse Practitioner, Division of Gynecologic Oncology

Jaclyn Shaver

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

David M O'Malley

Moderator

David M O'Malley

MD

The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

Meeting space has been assigned to provide a symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    MODULE 1: Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

    • Similarities and differences between germline and somatic genetic mutations
    • Incidence and clinical significance of BRCA mutations and other germline or somatic alterations (eg, PALB2, ATM, RAD51C/D) in ovarian cancer
    • Current roles of next-generation sequencing and germline sequencing for advanced ovarian cancer; similarities and differences among available genetic testing platforms
    • Purpose and potential benefits of genetic counseling after a diagnosis of ovarian cancer

    MODULE 2: Role of PARP Inhibitors for Advanced Ovarian Cancer

    • Mechanism of antitumor activity of PARP inhibitors, and rationale for their use as maintenance therapy for patients with newly diagnosed advanced ovarian cancer
    • Long-term findings from Phase III studies with olaparib, olaparib/bevacizumab and niraparib maintenance for newly diagnosed ovarian cancer
    • Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab or niraparib maintenance
    • Current clinical utility, if any, of PARP inhibitors for relapsed/refractory ovarian cancer, including among patients who have experienced disease progression on or after prior PARP inhibitor therapy

    MODULE 3: Side Effects and Other Practical Considerations with PARP Inhibitors

    • Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
    • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with ovarian cancer
    • Optimal monitoring and management paradigms for common PARP inhibitor-related toxicities
    • Long-term risk of acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
    • Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

    MODULE 4: Current and Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment

    • Frequency of and scientific rationale for targeting folate receptor alpha (FRα) in ovarian cancer
    • Mechanism of action and structural components of mirvetuximab soravtansine
    • Published research findings with mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer
    • FDA approval of mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer; implications for biomarker assessment and current management
    • Early findings with mirvetuximab soravtansine for FRα-high, platinum-sensitive advanced ovarian cancer; ongoing evaluation and potential utility in this setting

    MODULE 5: Toxicities Associated with Mirvetuximab Soravtansine

    • Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
    • Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
    • Importance of collaboration with eye care specialists for patients receiving mirvetuximab soravtansine
    • Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

    MODULE 6: Other Approved and Investigational Antibody-Drug Conjugates for Ovarian Cancer

    • Frequency of HER2 expression in advanced ovarian cancer; optimal timing of and approach to testing
    • FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for ovarian cancer management
    • Biological rationale for targeting CDH6 for ovarian cancer; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
    • Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced ovarian cancer

    MODULE 7: Current Role of Relacorilant for Advanced OC

    • Incidence and clinical relevance of glucocorticoid receptor (GR) overexpression in ovarian cancer
    • Mechanism of action of the selective GR modulator relacorilant; rationale for combining relacorilant with chemotherapy for advanced ovarian cancer
    • Published efficacy and safety findings with relacorilant in combination with nab paclitaxel versus nab paclitaxel alone for platinum-resistant advanced ovarian cancer
    • Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant advanced ovarian cancer, and integration into current clinical algorithms

    MODULE 8: Tolerability Considerations with Relacorilant/Nab Paclitaxel

    • Rationale for nab paclitaxel as a therapeutic partner for relacorilant; necessity of avoiding corticosteroid use with relacorilant
    • Tolerability profile of relacorilant/nab paclitaxel in published clinical trials; relative contributions of each agent in terms of toxicities
    • Incidence and severity of cytopenias with relacorilant/nab paclitaxel; appropriate monitoring and management
    • Rates of and strategies to manage peripheral neuropathy with relacorilant/nab paclitaxel

    MODULE 9: Utility of Immune Checkpoint Inhibition for Advanced OC

    • Historical outcomes documented with anti-PD-1/PD-L1 antibodies as monotherapy for advanced ovarian cancer; potential explanations for the lack of activity with these agents for ovarian cancer relative to other tumor types
    • Emerging data demonstrating a progression-free survival advantage with the addition of pembrolizumab to chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer
    • Impact of PD-L1 expression on overall survival in the aforementioned emerging data set; potential implications for biomarker analysis for advanced ovarian cancer
    • Potential clinical role of pembrolizumab for platinum-resistant recurrent ovarian cancer

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and counsel appropriate individuals regarding personalized treatment recommendations.
    • Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
    • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
    • Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
    • Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
    • Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
    • Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
    • Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

    Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

    MODERATOR — Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.